RNA-binding protein RNPC1: acting as a tumor suppressor in breast cancer

BMC Cancer

Table 1 The association between RNPC1 mRNA expression and clinicopathologic features of breast cancer

Clinicopathologic parameters	Number of case	RNPC1	RNPC1	p-value
		Low expression	High expression
Age (years)
≤55	68	42	26	0.109
>55	53	40	13
Tumor Size (cm)
≤2	38	24	14	0.463
>2	83	58	25
TNM stage
I	24	11	13	0.010
II + III	97	71	26
Lymph node metastasis
≤3	96	69	27	0.058
>3	25	13	12
Grade
I	7	2	5	0.066
II	67	50	17
III	30	18	12
unclear	17	12	5
ER status
Negative	40	22	18	0.097
Positive	70	51	19
unclear	11	9	2
PR status
Negative	58	42	16	0.294
Positive	63	40	23
Her2 status
Negative	81	56	25	0.298
Positive	32	19	13
suspect	8	7	1
Ki67
≤15 %	43	30	13	0.430
>15 %	52	40	12
CK5/6
Negative	46	35	11	0.830
Positive	15	11	4
P53
Negative	42	26	16	0.042
Positive	52	42	10
PCNA
Negative	2	1	1	0.567
+	36	27	9
++	22	18	4
+++	12	8	4
Histology
ductal	106	71	35	0.622
special	15	11	4

ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2.
TNM classification according to the Union Internationale Contre le Cancer criteria. HER2 positivity 3+ in immunohistochemistry or positive fluorescent in situ hybridisation test.

ISSN: 1471-2407